


Stabilis



Acetylsalicylic acid lysinate



Noms commerciaux

Acetilsalicinato de lisina	Portugal
Aspegic	Belgique, Chili, Espagne, France, Italie, Luxembourg, Maroc, Pays bas, Portugal, Suisse, Tunisie
Aspidol	Italie
Aspirin IV	Allemagne
Aspirina Richet	Argentine
Aspisol	Allemagne
Flectadol	Italie
Inyesprin	Espagne
Kardegic	France, Hongrie
Kardiren	Hongrie
Laspal	Pologne













Stabilité en mélange

		140 mg/ml	25°C		Thiocolchicoside : 1 mg/ml	3		1859



Compatibilités

	Acetylsalicylic acid lysinate : 10 mg/ml Hydrocortisone sodium succinate : 2 mg/ml		4698
	Acetylsalicylic acid lysinate : 10 mg/ml Insulin : 1 UI/ml		4698
			3838
	Acetylsalicylic acid lysinate : 10 mg/ml Magnesium sulfate : 6 mg/ml		4698
	Acetylsalicylic acid lysinate : 10 mg/ml Nefopam : 0,08 mg/ml		4698
			2139
	Acetylsalicylic acid lysinate : 8.33 mg/ml Pantoprazole sodium : 8 mg/ml		

	Acetylsalicylic acid lysinate : 10 mg/ml Phytomenadione : 0,2 mg/ml		4698
	Acetylsalicylic acid lysinate : 10 mg/ml Potassium chloride : 1340 mEq/l		4698
	 Acetylsalicylic acid lysinate Reteplase		2212
	Acetylsalicylic acid lysinate : 10 mg/ml Thiamine hydrochloride : 1 mg/ml		4698
	Acetylsalicylic acid lysinate : 142.86 mg/ml Thiocolchicoside : 0.57 mg/ml		1859


























Bibliographie

	Type	Source
1859	Revue	Anacardio R, Perilli O, Pagnanelli F, Bartolini S, gentile MM, Mazzeo P, Carlucci G. Physicochemical compatibility between thiocolchicoside injections (Miotens®) and pharmaceutical products frequently used for combined therapy. Il Farmaco 2002 ; 57: 925-930.
2139	Revue	Serrurier C, Chenot ED, Vigneron J, May I, Demor? B. Assessment of injectable drug's administration in two intensive care units and determination of potential physico-chemical incompatibilities. EJHP Science 2006 ; 12,5: 96-99.
2212	Laboratoire	Reteplase (Rapilysin®) - Summary of Product Characteristics Actavis UK Ltd 2015
3838	Laboratoire	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
4698	Revue	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022



Dictionnaire

 Antalgique	 Injectable
 Noms commerciaux	 Stabilité en mélange
 Contenant	 Solvant
 Concentration	 Température
 Conservation	 Molécule
 Durée de stabilité	 Bibliographie
 Verre	 Aucun
 Heure	 Compatibilités
 Compatible	 Chlorure de sodium 0,9%
 Incompatibilité non précisée	 Incompatible
 Changement de couleur	 Bibliographie
 Dictionnaire	